Starlix, Zaditor Paragraph IV Filings
This article was originally published in The Pink Sheet Daily
Executive Summary
The first ANDA with a Paragraph IV certification for Novartis' antidiabetic agent Starlix (nateglinide) was submitted to FDA Dec. 22, according to the agency's Feb. 16 updated list of filings